First AD

Second AD

Future Perspectives on ADCs in Breast Cancer 

Video content above is prompted by the following:

Please review some ongoing clinical trials and studies utilizing investigational ADCs in breast cancer that are in progress that may be interesting. (See below for a few suggestions. Please include others if not included.)

Bartsch R. et al. Patritumab deruxtecan (HER3-DXd) in Active Brain Mets. TUXEDO-3 Phase II trial. ASCO 2024 Abstract

Bardia A et al, Final Results TROPION-Breast01. ESMO 2023 Abstract.

Breast Cancer

 Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

OncLive Peer Exchange® 

® Peer Exchange video program comprises lively expert panel discussions feature peer-to-peer exchanges providing authoritative insights, opinions, and perspectives on important issues facing today’s health care professionals. Episodes focus on updates and insights across solid and hematologic malignancies, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecological cancers, and hematologic malignancies. 

Strategies to Manage Antibody Drug Conjugates (ADC) - Related Toxicities in Breast Cancer 

Insights

UCSF Helen Diller Family Comprehensive Cancer Center

Cancer Centers

Partner

Panelists discuss how ongoing clinical trials of investigational antibody-drug conjugates (ADCs) are advancing treatment options for breast cancer, particularly in patients with active brain metastases and advanced disease.